The Significance of a Pathologic Complete Response in Patients With Soft Tissue Sarcoma
Ce dossier présente deux études : un essai de phase II évaluant l'efficacité et la sécurité de la trabectédine associée à une radiothérapie chez 46 patients atteints d'un liposarcome myxoïde et une analyse de la valeur pronostique de la réponse pathologique complète chez des patients atteints d'un sarcome des tissus mous
This issue of JAMA Oncology includes the results of 3 prospective clinical trials for patients with soft tissue sarcomas, Trabectedin and Radiotherapy in Soft Tissue Sarcoma (TRASTS), and a combined analysis of NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9514 and 0630, that offer important insight into the clinical implications of a pathologic complete response (pCR) following neoadjuvant radiation or chemoradiation therapy. The studies also highlight the trend to design clinical trials for patients with soft tissue sarcomas in a more biologically driven fashion to better account for disease heterogeneity by comparing differences in clinical outcomes between histologic subtypes and, whenever possible, design studies tailored to 1 or a small number of histotypes with shared biologic features.
JAMA Oncology , éditorial, 2022